Editas in three-year research deal with SR-TIGET

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) partnered with Fondazione Telethon (Milan, Italy) and Ospedale San Raffaele (Milan, Italy) to focus on R&D of genome-edited hematopoietic stem cell and T cell therapies. The Italian groups operate the joint venture San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET), which is focused on gene and cell therapies.

In their three-year collaboration, the partners will aim to develop gene correction strategies to treat rare diseases, including two specified but undisclosed indications in the blood and bone marrow. Financial terms are undisclosed, as are details on IP ownership. ...